Roivant Sciences Ltd.

Key metrics

Financial performance

Over the last 5 fiscal years Roivant Sciences Ltd.'s revenue declined from $23.80M to $8.26M, a compound annual decline rate of 19.1%. Net profit margin compressed from -3400.9% to -3629.2% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (868 filings)

Recent press releases

• Priovant Expands Brepocitinib Development Program NEW Phase 2B32026-04-02

  Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) | Roivant Sciences Ltd.

• Immunovant’s Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findings2026-04-02

  Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Roivant Sciences Ltd.

• Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update | Roivant Sciences Ltd.2026-03-31

  IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026

• Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026 | Roivant Sciences Ltd.2026-03-31

  To access the conference call by phone, please register online using this registration link . The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.

• New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis | Roivant Sciences Ltd.2026-03-28

  New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

Similar companies

The largest companies sharing Roivant Sciences Ltd.'s SEC industry classification (pharmaceutical preparations).